Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study

被引：0
|
作者：
Abelman, Rachel Occhiogrosso
Spring, Laura
Niemierko, Andrzej
Abraham, Elizabeth
McNeice, Mary
Goff, Jennifer
Valenti, Amanda
Wander, Seth Andrew
Isakoff, Steven J.
Moy, Beverly
Juric, Dejan
Vidula, Neelima
Waks, Adrienne Gropper
Parsons, Heather Anne
Ellisen, Leif W.
Tolaney, Sara M.
Bardia, Aditya
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[3] UCLA Hlth Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1102
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
    Bardia, A.
    Spring, L. M.
    Juric, D.
    Partridge, A.
    Ligibel, J.
    Kuter, I.
    Peppercorn, J.
    Parsons, H.
    Ryan, P.
    Chawla, D.
    Attaya, V.
    Fitzgerald, D. M.
    Viscosi, E.
    Lormill, B.
    Shellock, M.
    Moy, B.
    Tolaney, S. M.
    Ellisen, L. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S394 - S394
  • [2] Metastatic triple-negative Breast Cancer (mTNBC) First-in-class Therapy with Sacituzumab Govitecan
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 64 - 65
  • [3] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
    Schoellmann, Claudia
    BREAST CARE, 2022, 17 (01)
  • [4] Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results
    Seneviratne, Lasika C.
    Harnden, Kathleen Kiernan
    Blau, Sibel
    Danso, Michael A.
    Berz, David
    Guaqueta, Delia Constanza
    Schwerkoske, John F.
    O'Shaughnessy, Joyce
    Patt, Debra A.
    Bardia, Aditya
    McCann, Kelly Elizabeth
    Beelen, Andrew Paul
    Zhang, Jingshan
    Yi, John S.
    Hurvitz, Sara A.
    Mardones, Mabel Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
  • [6] Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Carey, Lisa A.
    Zelnak, Amelia
    Rugo, Hope S.
    Dalenc, Florence
    Nanda, Rita
    Danso, Michael
    Saghatchian, Mahasti
    Kalinsky, Kevin
    Firmin, Nelly
    Ruiz-Borrego, Manuel
    Favret, Anne
    Sun, Jun
    Schwartzberg, Lee
    Hilton, Christie
    Omene, Coral
    Young, Robyn
    Hurvitz, Sara A.
    Harting, Eliza
    Phan, See
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [7] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
    Schreiber, Anna R.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
  • [8] Efficacy of Sacituzumab Govitecan (SG) in Patients with metastatic triple negative Breast Cancer (mTNBC) by HER2 Immunohistochemistry (IHC) Status: Results from the Phase 3 ASCENT Study
    Hegewisch-Becker, S.
    Hurvitz, S. A.
    Bardia, A.
    Punie, K.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Carey, L. A.
    Rugo, H. S.
    Yoon, O. K.
    Pan, Y.
    Delaney, R.
    Hofsess, S.
    Hodgkins, P.
    Phan, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 104 - 105
  • [9] A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC)
    Barroso-Sousa, Romualdo
    Trippa, Lorenzo
    Li, Tianyu
    Keenan, Tanya E.
    Winship, Grace
    Andrews, Chelsea
    Osmani, Wafa
    Overmoyer, Beth
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Duda, Dan G.
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [10] A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).
    Barroso-Sousa, Romualdo
    Guo, Hao
    Barry, William Thomas
    Winship, Grace
    Overmoyer, Beth
    Duda, Dan G.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345